Table 1.
Clinicopathological properties of patient and UBE2O expression in prostate cancer.
| Prognosis Factors |
n (%) (n = 382) |
|---|---|
| Age (years) | 67.0 ± 0.4 |
| PSA (ng/mL) | |
| <10 | 220 (57.6%) |
| 10–20 | 97 (25.4%) |
| >20 | 65 (17.0%) |
| Gleason | |
| ≤6 | 52 (13.6%) |
| 7 | 155 (40.6%) |
| 8–10 | 175 (45.8%) |
| Pathological stage | |
| ≤T2 | 162 (42.4%) |
| ≥T3 | 220 (57.6%) |
| Seminal vesicle invasion | |
| Negative | 319 (83.5%) |
| Positive | 63 (16.5%) |
| Lymph node involvement | |
| Negative | 370 (96.9%) |
| Positive | 12 (3.1%) |
| Surgical margin * | |
| Negative | 115 (57.5%) |
| Positive | 85 (42.5%) |
| Expression of UBE2O # | |
| 0 | 0 |
| 1 | 120 (33.8%) |
| 2 | 154 (43.4%) |
| 3 | 81 (22.8%) |
UBE2O grade—0: negative 1: weak 2: moderate 3: strong. Age was expressed as Mean ± standard error. * The number of surgical margin could be evaluated in only 200 with prostate cancer of our hospital from 382 patients. # The number of UBE2O immunohistochemical expression could be evaluated in only 355 from 382 patients with prostate cancer of our hospital and purchased TMA.